5-((5-(4-chlorophenyl)furan-2-yl)methylene)thiazolidine-2,4-dione | 331652-44-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 5-((5-(4-chlorophenyl)furan-2-yl)methylene)thiazolidine-2,4-dione
• 英文别名: 5-[5-(4-chloro-phenyl)furan-2-ylmethylene]thiazolidine-2,4-dione；5-[[5-(4-Chlorophenyl)furan-2-yl]methylidene]-1,3-thiazolidine-2,4-dione
• CAS: 331652-44-9
• 化学式: C₁₄H₈ClNO₃S
• 分子量: 305.741
• InChiKey: RRAONENOLKGLHR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  84.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-((5-(4-chlorophenyl)furan-2-yl)methylene)thiazolidine-2,4-dione 、 3-甲氧基氯苄 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.17h， 以80%的产率得到3-(3-methoxybenzyl)-5-((5-(4-chlorophenyl)furan-2-yl)methylene)thiazolidine-2,4-dione
  参考文献：
  名称：

  Inhibition of gastric H⁺, K⁺-ATPase by novel thiazolidinone derivatives

  摘要：

  In a program to identify new anti-ulcer compounds, a series of novel substituted thiazolidinone derivatives 5(a-j) were synthesized and screened for their in vitro H+, K+-ATPase inhibitory activity. The synthesized compounds were characterized by nuclear magnetic resonance (1H-NMR), liquid chromatography-mass spectrometry (LCMS) and fourier transform infrared (FTIR) analysis. We have briefly investigated the structure-activity relation (SAR) studies and reveal that the nature of position of the fluorine atom influences the anti-ulcer activity. Among the synthesized compounds 5b, 5c and 5e showed 4 and 10-fold higher H+, K+-ATPase activity when compared with those of other derivatives 5a, 5f, 5g and 5j, respectively. H+, K+-ATPase activity of 5b, 5c and 5e were comparable with those of known H+, K+-ATPase blocker lansoprazole which is a potential anti-ulcer drug.

  DOI：

  10.1080/17415991003702621
• 作为产物：
  描述：

  5-甲醛基呋喃-2-硼酸 在 四(三苯基膦)钯 、 potassium carbonate 、 溶剂黄146 、 β-丙氨酸 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 6.0h， 生成 5-((5-(4-chlorophenyl)furan-2-yl)methylene)thiazolidine-2,4-dione
  参考文献：
  名称：

  Development of a novel class of B-RafV600E-selective inhibitors through virtual screening and hierarchical hit optimization

  摘要：

  细胞信号通路关键节点的致癌突变与肿瘤的发生和发展有关。B-Raf蛋白激酶是典型MAPK信号级联的关键枢纽，在多种人类癌症，尤其是恶性黑色素瘤中发生突变。最常见的B-RafV600E突变体表现出较高的激酶活性，导致MAPK通路的组成性激活，从而使其成为一种很有希望的癌症治疗药物靶点。在此，我们介绍了通过多步虚拟筛选和分层命中优化开发新型 B-RafV600E 选择性抑制剂的情况。通过虚拟筛选，我们确定了九种具有低微摩尔 IC50 值的命中化合物作为 B-RafV600E 抑制剂。随后的基于支架的类似物搜索和药物化学工作显著提高了抑制剂的效力和对癌基因的选择性。其中，22f 和 22q 化合物的 IC50 值达到纳摩尔级，在体外对 B-RafV600E 具有选择性，对携带 B-RafV600E 的癌细胞具有独特的细胞毒性。

  DOI：

  10.1039/c2ob26081f

文献信息

• Development of a novel class of B-RafV600E-selective inhibitors through virtual screening and hierarchical hit optimization
  作者：Xiangqian Kong、Jie Qin、Zeng Li、Adina Vultur、Linjiang Tong、Enguang Feng、Geena Rajan、Shien Liu、Junyan Lu、Zhongjie Liang、Mingyue Zheng、Weiliang Zhu、Hualiang Jiang、Meenhard Herlyn、Hong Liu、Ronen Marmorstein、Cheng Luo

  DOI：10.1039/c2ob26081f

  日期：——

  Oncogenic mutations in critical nodes of cellular signaling pathways have been associated with tumorigenesis and progression. The B-Raf protein kinase, a key hub in the canonical MAPK signaling cascade, is mutated in a broad range of human cancers and especially in malignant melanoma. The most prevalent B-RafV600E mutant exhibits elevated kinase activity and results in constitutive activation of the MAPK pathway, thus making it a promising drug target for cancer therapy. Herein, we describe the development of novel B-RafV600E selective inhibitors via multi-step virtual screening and hierarchical hit optimization. Nine hit compounds with low micromolar IC50 values were identified as B-RafV600E inhibitors through virtual screening. Subsequent scaffold-based analogue searching and medicinal chemistry efforts significantly improved both the inhibitor potency and oncogene selectivity. In particular, compounds 22f and 22q possess nanomolar IC50 values with selectivity for B-RafV600Ein vitro and exclusive cytotoxicity against B-RafV600E harboring cancer cells.

  细胞信号通路关键节点的致癌突变与肿瘤的发生和发展有关。B-Raf蛋白激酶是典型MAPK信号级联的关键枢纽，在多种人类癌症，尤其是恶性黑色素瘤中发生突变。最常见的B-RafV600E突变体表现出较高的激酶活性，导致MAPK通路的组成性激活，从而使其成为一种很有希望的癌症治疗药物靶点。在此，我们介绍了通过多步虚拟筛选和分层命中优化开发新型 B-RafV600E 选择性抑制剂的情况。通过虚拟筛选，我们确定了九种具有低微摩尔 IC50 值的命中化合物作为 B-RafV600E 抑制剂。随后的基于支架的类似物搜索和药物化学工作显著提高了抑制剂的效力和对癌基因的选择性。其中，22f 和 22q 化合物的 IC50 值达到纳摩尔级，在体外对 B-RafV600E 具有选择性，对携带 B-RafV600E 的癌细胞具有独特的细胞毒性。
• Inhibition of gastric H⁺, K⁺-ATPase by novel thiazolidinone derivatives
  作者：S. Chandrappa、K. Vinaya、B. M. Srikanta、C. S. Ananda Kumar、D. S. Prasanna、N. R. Thimmegowda、Shylaja M. Dharmesh、K. S. Rangappa

  DOI：10.1080/17415991003702621

  日期：2010.6

  In a program to identify new anti-ulcer compounds, a series of novel substituted thiazolidinone derivatives 5(a-j) were synthesized and screened for their in vitro H+, K+-ATPase inhibitory activity. The synthesized compounds were characterized by nuclear magnetic resonance (1H-NMR), liquid chromatography-mass spectrometry (LCMS) and fourier transform infrared (FTIR) analysis. We have briefly investigated the structure-activity relation (SAR) studies and reveal that the nature of position of the fluorine atom influences the anti-ulcer activity. Among the synthesized compounds 5b, 5c and 5e showed 4 and 10-fold higher H+, K+-ATPase activity when compared with those of other derivatives 5a, 5f, 5g and 5j, respectively. H+, K+-ATPase activity of 5b, 5c and 5e were comparable with those of known H+, K+-ATPase blocker lansoprazole which is a potential anti-ulcer drug.